This trial is evaluating whether Durvalumab (MEDI4736) will improve 2 primary outcomes, 10 secondary outcomes, and 1 other outcome in patients with Carcinoma, Non-Small-Cell Lung. Measurement will happen over the course of 12 months.
This trial requires 671 total participants across 2 different treatment groups
This trial involves 2 different treatments. Durvalumab (MEDI4736) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
The most commonly used treatments for [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) are radiotherapy, chemotherapy, surgery, and biogenetic therapy. In advanced stages, radiotherapy may be used alone or with chemotherapy and biogenetic therapy. Survival depends on the type of treatment given depending on the stage of the cancer.
Carcinoma, non-small-cell, is a complex disease that results from the interaction of multiple etiologic influences, including lifestyle and environmental factors. These factors cannot simply be measured, nor can they be simplified into discrete molecular pathways (and specific genes and proteins) so that these markers may reflect an underlying process.
Although surgery and chemotherapy are highly effective for nonsquamous carcinoma, in an institutional referral centre with a high prevalence of locally advanced disease the majority of surgically resected patients can expect to have long-lasting cancer remission or symptom-free survival with chemotherapy. However, only a minority of patients can expect to survive more than 2 years.
Cancers of lung and bronchus are both common diseases with significant financial cost and significant human suffering. A large number of lung and bronchus cancers would not be detected without careful history and physical examination by general physicians and by respiratory physicians as a part of a primary care physician's work. The financial resource spent to screen for lung and bronchial cancer should be balanced with an evaluation of cost-effectiveness.
Cancer of the lung is a significant cause of deaths in the United States, representing approximately 8.6% of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) deaths and 18.5% of deaths from lung cancer. Lung carcinoma represents 15.0% of new cases of cancer diagnosed in the United States in 2009. Results from a recent paper will help physicians estimate the future burden of lung cancer on the United States health care system.
The most common signs of nonsmall-cell [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer)s are cough, dyspnea, chest pain, hemoptysis, hematochezia, and hemoptysis with hematochezia with or without hematochezia, with or without hemoptysis. The presence of any of these symptoms is significant. Most nonsmall-cell cancers are diagnosed on the basis of symptoms and physical assessment.
This review [did] not support recent randomized controlled trials, meta-analyses of pooled data or a guideline incorporating the literature; therefore, the evidence did not support any particular approach that is currently considered to be valid for carcinoma, non-small-cell lung. The most recent reviews (as of 2007) do not provide information in a way that is helpful and complete for clinicians. Further research [into the management of carcinoma, non-small-cell lung is necessary] if we are to improve patient care and outcomes in metastatic cancer.
Only one patient at our institution survived for more than 3 years, with a median survival interval between diagnoses of 3.7 years. The survival rates for our patients were 2% for synchronous disease, 21% for metachronous disease, and 28% for patients with Stage I or II disease.
Median time to first dose of durvalumab was 20 d (interquartile interval 15-42). Patients who took durvalumab had a shorter duration of the medication-induced flare-up and less nausea when compared with those who did not take durvalumab. Median time to best sustained reduction in tumor size was 34 and 45 d in patients who received 100 and 200 mg of durvalumab, respectively. Because these results are from one small study of patients who received a single dose of 200 mg, and may not be generalizable to all people, further study with larger patient populations is needed to validate these results.
For the present study, we determined the age of patients who had received treatment for NSCLC and the stage of the disease. The average age of patients was 63 years. Patients of ages 70 years or more had most commonly received treatment. Recent findings of the study are preliminary. To ensure validity, results should be confirmed on a larger population.
Although NSCLC has a dismal prognosis, almost all metastatic lesions are found in the lungs. If there are metastases present and the primary tumor proves not completely resected, the possibility of a complete surgical resection of the primary tumor does not appear to be significant, and the patient can expect a better prognosis.